Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
NCT00787917 · Novartis Pharmaceuticals · PHASE4 · terminated · last registry update 2011-09-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IGHE within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2012-07-23Also stopped (withdrawn): Novartis Pharmaceuticals, QGE031 + Placebo (NCT01451450)
- 2012-06-08Results posted on the registry: Novartis Pharmaceuticals, omalizumab + Placebo (NCT01007149)
- 2011-12-08Results posted on the registry: Genentech, Inc., omalizumab (Xolair) + placebo (NCT00096954)
- 2011-11-17Results posted on the registry: Novartis Pharmaceuticals, Omalizumab + Placebo (NCT00870584)
- 2011-10-21Results posted on the registry: Novartis, Omalizumab 75-375 mg + Placebo to omalizumab (NCT00481676)
- 2011-10-13Results posted on the registry: Genentech, Inc., omalizumab (Xolair) + placebo (NCT00314574)
- 2011-09-09Results posted on the registry: Genentech, Inc., omalizumab + placebo (NCT00866788)
- 2011-08-03Results posted on the registry: Novartis Pharmaceuticals, Omalizumab + Placebo (NCT00079937)
- 2011-08-01Results posted on the registry: Novartis Pharmaceuticals, Omalizumab + placebo (NCT00454051)
- 2011-07-25Results posted on the registry: Novartis, Omalizumab (NCT00264849)
- 2011-06-03Results posted on the registry: Novartis Pharmaceuticals, Depigoid + Omalizumab (NCT00396409)
- 2011-05-23Results posted on the registry: Novartis, Omalizumab + Inhaled corticosteroids (ICS) (NCT00567476)
- 2011-05-16Results posted on the registry: Novartis, Placebo + Omalizumab (NCT00267202)
- 2011-04-27Results posted on the registry: Novartis, omalizumab (NCT00500539)
- 2011-04-11Phase 3 first posted: University of Zurich, injections (NCT01333293)
- 2011-04-05Phase 3 first posted: Novartis Pharmaceuticals, Omalizumab (NCT01328886)
- 2011-03-09Also stopped (terminated): University of California, Los Angeles, Xolair injections (NCT00784485)
- 2011-02-14Results posted on the registry: Genentech, Inc., Cohort I + Cohort 2 (NCT00777764)
- 2011-02-14Results posted on the registry: Novartis, Xolair + Placebo (NCT00624832)
- 2011-02-14Phase 3 first posted: Fondazione IRCCS Policlinico San Matteo di Pavia, omalizumab (NCT01294878)
- 2011-02-09Phase 3 first posted: Genentech, Inc., Placebo + Omalizumab (NCT01292473)
- 2011-02-01Phase 3 first posted: Genentech, Inc., Omalizumab + Placebo (NCT01287117)
- 2010-12-22Phase 3 first posted: Genentech, Inc., Omalizumab + Placebo (NCT01264939)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision